Page 1

CRISPRI THERAPEUTICS CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results - More than 45 patients have been dosed with CTX001TM across CLIMB - Thal - 111 and CLIMB - SCD - 121 to date ; completion of enrollment in both trials is expected in 2021 -Received Orphan Drug Designation ( ODD ) for Phase 1 clinical trial of CTX130TM for the treatment of T - cell lymphoma -Enrollment ongoing in CTX110TM , CTX120TM and CTX130 clinical trials ZUG , Switzerland and CAMBRIDGE , Mass . , July 29 , 2021- CRISPR Therapeutics ( Nasdaq : CRSP ) , a biopharmaceutical company focused on creating transformative gene - based medicines for serious diseases , today reported financial results for the second quarter ended June 30 , 2021 . " We concluded an important quarter in which we reported notable data from our hemoglobinopathies program while rapidly advancing our entire clinical and pre - clinical portfolio and our capabilities , " said Samarth Kulkarni , Ph.D. , Chief Executive Officer of CRISPR Therapeutics . " Updated clinical data on CTX001 presented at EHA demonstrate consistency and durability , further validating the promise of a functional cure for sickle cell disease and beta thalassemia . We expect to report clinical data from our immuno oncology programs later this year , and to file multiple INDs for our regenerative medicine and in vivo programs in the next 18 to 24 months . In addition , we continue to expand our portfolio and access best in - class capabilities through collaborations , such as those recently announced with Capsida Biotherapeutics and Nkarta Therapeutics . " Recent Highlights and Outlook Beta Thalassemia and Sickle Cell Disease O In April , CRISPR Therapeutics and Vertex announced an amendment to their collaboration for CTX001 . In connection with the completion of the transaction in June , Vertex made a $ 900 million upfront payment to CRISPR Therapeutics . Data from 22 patients with at least three months of follow - up after CTX001 infusion were presented at the Annual European Hematology Association Virtual Congress ( EHA ) in June and continued to build the profile of a functional cure for patients with transfusion dependent beta thalassemia ( TDT ) and severe sickle cell disease ( SCD ) , showing consistent and durable benefit with longer term data from a larger population of patients . Enrollment and dosing are ongoing in the clinical studies for CTX001 and more than 45 patients have been dosed across the programs to date . The companies anticipate achieving target enrollment in both studies in the third quarter of 2021 , with regulatory filings possible in the next 18 to 24 months .